Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer

Plain-language summary

This study evaluates the drug Teniposide in patients with c-Myc-driven extensive-stage small cell lung cancer. It enrolls people aged 18-75 with c-Myc-driven extensive-stage small cell lung cancer who have received at least one prior chemotherapy. The study is Phase 2 and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Recruiting

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Intervention

Teniposide administration

Start date

2/7/2025

Estimated completion

12/31/2026

Countries

China

Related genes

Locations

• Shanghai, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. extensive stage small cell lung cancer
2. Progression after receiving at least one chemotherapy drug treatment in the past;
3. ECOG score 0-1
4. c-Myc-driven
5. Expected survival period ≥3 months
6. Age: 18-75 years old;
7. The informed consent form complies with the ICH-GCP principles.

Exclusion Criteria:

1. No measurable lesions
2. Other severe and persistent diseases or organ system dysfunction;
3. Women planning pregnancy or men planning family planning;
4. Women who are pregnant or breastfeeding;
5. Those who cannot follow the research protocol provided by the investigator.